首页> 外文期刊>Asian cardiovascular & thoracic annals >Stem cell experiments and initial clinical trial of cellular cardiomyoplasty.
【24h】

Stem cell experiments and initial clinical trial of cellular cardiomyoplasty.

机译:干细胞实验和细胞心肌成形术的初步临床试验。

获取原文
获取原文并翻译 | 示例
           

摘要

Growing myocardial cells from human stem cells and stem cell transplantation to repair injured myocardium are new frontiers in cardiovascular research. The 1st stage of this study was conducted to determine whether transplantation of autologous bone marrow stem cells into infarcted myocardium of sheep could differentiate into beating cardiomyocytes. The 2nd stage was to demonstrate transdifferentiation of human bone marrow mesenchymal stem cells to precursor cardiomyocytes in vitro, using a novel conditioning medium. In the 3rd stage, a clinical trial of stem cell implantation in patients with severe myocardial dysfunction involved injection of peripheral blood-derived endothelial precursor cells in 11 patients and autologous bone marrow mononuclear cells in 29. A marginal improvement in myocardial function was noted at 3 months (mean increase in ejection fraction, 6% +/- 1%), although it plateaued at 6 months. The trial proved to be safe because there was no procedure-related mortality. There is growing optimism that stem cell therapy may delay heart transplantation.
机译:来自人类干细胞的心肌细胞的生长以及修复受损心肌的干细胞移植是心血管研究的新领域。这项研究的第一阶段是确定自体骨髓干细胞移植到绵羊梗死心肌中是否可以分化为跳动的心肌细胞。第二阶段是使用新型条件培养基在体外证明人骨髓间充质干细胞向前体心肌细胞的转分化。在第3阶段,对患有严重心肌功能障碍的患者进行干细胞植入的临床试验涉及11位患者注射外周血源性内皮前体细胞,以及29位患者注射自体骨髓单个核细胞。在3位发现心肌功能略有改善个月(射血分数平均增加6%+/- 1%),尽管在6个月达到平稳。该试验被证明是安全的,因为没有与手术相关的死亡率。人们越来越乐观地认为干细胞治疗可能会延迟心脏移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号